- BLA filing of Anktiva + BCG in BCG-unresponsive cancer in Situ non-muscle invasive bladder cancer patients is expected Q1 of 2022.
- Nant Cancer Vaccine combination with Anktiva, PD-L1 t-haNK, aldoxorubicin, low dose chemotherapy has established proof of concept in previously treated pancreatic cancer patients.
- Memory-like cytokine-enriched natural killer cells established proof of concept in treating patients with acute myeloid leukemia.
- ImmunityBio had $317.9 million in cash as of December 31, 2021; Enough to fund its operations for at least the next 12 months.
For further details see:
ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter